ACUT Stock Overview
A clinical stage diagnostics company, focuses on developing and commercializing products for the treatment and management of various cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
AccuStem Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.45 |
| 52 Week High | US$0.72 |
| 52 Week Low | US$0.22 |
| Beta | 3.03 |
| 1 Month Change | 85.95% |
| 3 Month Change | 28.57% |
| 1 Year Change | -25.12% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACUT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.7% | -0.1% | -0.5% |
| 1Y | -25.1% | -6.4% | 23.2% |
Return vs Industry: ACUT underperformed the US Biotechs industry which returned -7% over the past year.
Return vs Market: ACUT underperformed the US Market which returned 23% over the past year.
Price Volatility
| ACUT volatility | |
|---|---|
| ACUT Average Weekly Movement | 45.0% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACUT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ACUT's weekly volatility (45%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 3 | Wendy Blosser | accustem.com |
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing products for the treatment and management of various cancers. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company was founded in 2013 and is headquartered in New York, New York.
AccuStem Sciences, Inc. Fundamentals Summary
| ACUT fundamental statistics | |
|---|---|
| Market cap | US$5.11m |
| Earnings (TTM) | -US$1.38m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.7x
P/E RatioIs ACUT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACUT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.38m |
| Earnings | -US$1.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -1.8% |
How did ACUT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 11:42 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AccuStem Sciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|